Literature DB >> 20886705

[A possible association of fatal pneumonia with mutations of pandemic influenza A/H1N1 sw1 virus in the receptor-binding site of the HA1 subunit].

D K L'vov, E I Burtseva, A G Prilipov, V S Bogdanova, M Iu Shchelkanov, N V Bovin, E I Samokhvalov, I T Fediakina, P G Deriabin, L V Kolobukhina, Iu A Shtyria, E S Shevchenko, N A Malyshev, L N Merkulova, M V Bazarova, A I Maslov, N M Ishchenko, E A Iskhakova, S V Al'khovskiĭ, T V Grebennikova, G K Sadykova, D N L'vov, M M Zhuravleva, S S Iamnikova, O V Shliapnikova, A B Poglazov, S V Trushakova, V V Lavrishcheva, V A Aristova, E S Proshina, N N Vereshchagin, A G Kuz'michev, K B Iashkulov, S D Dzhambinov, B Ts Bushkieva, S M Eliseeva, S I Bystrakov, I A Sokolova, N I Dzhaparidzhe, Iu A Ledenev, A P Rosolovskiĭ, R V Gareev, V V Boldyreva, V Iu Anan'ev, N I Baranov, V N Gorelikov, Iu A Garbuz, V I Reznik, L I Ivanov, N N Zdanovskaia, N M Sergeeva, I A Podolianko, O V Elovskiĭ, M A Gromova, E E Kalaeva, S N Grigor'ev, Iu V Eremeeva, M V Dovgal', I Iu Fedelesh, E A Sakharova, V I Burtnik, L N Avdoshina, N P Shapiro, D V Maslov, V A Ianovich, V A Ott, G B Lebedev.   

Abstract

The paper gives the results of sequence analysis of 150 positive samples in real-time RT-PCR, including 47 autopsy materials from patients (including 10 pregnant women), who died from fatal pneumonia mainly in November-December 2009, in whom the lifetime etiological diagnosis had not been made and hence no early etiotropic therapy performed. 70% of the primary materials from the deceased patients were found to have pandemic influenza A(H1N1) v mutants in the lung tissue with D222G (15%), D222N (15%), D222E (2%) substitutions, as well as a mixture of mutants (38%). Nasopharyngeal lavages from 3 Chukotka deceased patients exhibited only consensus (nonmutant) D222 virus variants; there was a mixture of consensus and mutant virus variants in the trachea and a mixture of mutant ones in the lung. Preliminary data from the study of the interaction of the hemagglutinin of two strains having D222G and D222N mutations with 9 oligosaccharides imitating the variants of cell receptors for influenza A virus suggest that there is a double receptor specificity for alpha2'-3' and alpha2'-6'-sialosides with a preponderance of alpha2'-3'-specificity. Further spread of the mutants that have acquired a high virulence and preserved their capacity for the respiratory route of human infection may lead to the situation similar to that seen in the 1918-1919 pandemic. Another scenario for evolution of the virus is to preserve its receptor specificity for alpha2'-3'-sialosides and high virulence with losses of alpha2'-6' specificity and capacity for aerosol transmission, by damping the pandemic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886705

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  3 in total

1.  General Characteristics and Prognostic Factors of Pneumonia Cases Developed During Pandemic (H1N1) Influenza-A Virus Infection in Turkey.

Authors:  Tevfik Ozlu; Yılmaz Bülbül; Sezai Taşbakan; Hatice Kılıç; Tülin Kuyucu; Tekin Yıldız; Tarkan Ozdemir; Serap Duru; Funda Oztuna; Nalan Adıgüzel; Leyla Sağlam; Ayşin Şakar Coşkun; Tacettin Ornek; Gazi Gündüz; Ayten Filiz; Levent Ozdemir; Gülfer Okumuş
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

Review 2.  Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.

Authors:  Chao Jiang; Xingang Yao; Yulin Zhao; Jianmin Wu; Pan Huang; Chunhua Pan; Shuwen Liu; Chungen Pan
Journal:  Microbes Infect       Date:  2020-05-13       Impact factor: 2.700

3.  Characterization in vitro and in vivo of a pandemic H1N1 influenza virus from a fatal case.

Authors:  Ariel Rodriguez; Ana Falcon; Maria Teresa Cuevas; Francisco Pozo; Susana Guerra; Blanca García-Barreno; Pamela Martinez-Orellana; Pilar Pérez-Breña; Maria Montoya; Jose Antonio Melero; Manuel Pizarro; Juan Ortin; Inmaculada Casas; Amelia Nieto
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.